Form 4: Titan Pharmaceuticals Insider Choong Choon Hau Converts $500,000 Promissory Note to Common Stock

Choong Choon Hau, a director and 10% owner of Titan Pharmaceuticals, converted $500,000 of a convertible promissory note into 54,132 shares of common stock on March 18, 2024.

Summary

• On March 18, 2024, Choong Choon Hau, a director and 10% owner of Titan Pharmaceuticals, converted $500,000 of a convertible promissory note into 54,132 shares of common stock.
• The conversion also included $6,444.44 of outstanding accrued interest, with $1,933.33 allocated for tax withholding on the interest earned, resulting in a total sum payable of $504,501.11.
• The convertible promissory note was issued by Titan Pharmaceuticals on August 8, 2023.
• Following the conversion, there are no remaining outstanding amounts in principal or accrued interest under the convertible promissory note.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transaction itself is neither particularly positive nor negative, but the conversion of debt to equity could be seen as a slightly positive sign.

Positives

• The conversion of the promissory note eliminates debt from Titan Pharmaceuticals' balance sheet.
• The insider's decision to convert the note into equity could be interpreted as a sign of confidence in the company's future prospects.

Future Outlook

There is no future outlook information provided in this document.

Industry Context

This transaction is a routine disclosure of insider activity and doesn't provide significant insight into broader industry trends. However, it does reflect the financial relationship between the company and one of its key stakeholders.

Stakeholder Impact

• Shareholders may see a slight dilution of their ownership due to the issuance of new shares.
• The company's financial position is improved by the reduction of debt.

Key Dates

Keywords

Titan Pharmaceuticals, Choong Choon Hau, Convertible Promissory Note, Common Stock, Insider Transaction, Form 4, TTNP